Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).
Department of Dermatology, Stanford University, Redwood City, California; Dermatology Division, Washington University Medical Center, Seattle. Electronic address: gkwon@stanford.edu.
Gina P
GP
Kwon
Department of Dermatology, Stanford University, Redwood City, California.
Mina Sarah
MS
Ally
Department of Dermatology, Stanford University, Redwood City, California.
Irene
I
Bailey-Healy
Department of Dermatology, Stanford University, Redwood City, California.
Anthony E
AE
Oro
Department of Dermatology, Stanford University, Redwood City, California; Department of Pathology, Stanford University, Redwood City, California.
Jinah
J
Kim
Department of Dermatology, Stanford University, Redwood City, California.
Anne Lynn
AL
Chang
Department of Dermatology, Stanford University, Redwood City, California.
Sumaira
S
Aasi
Department of Dermatology, Stanford University, Redwood City, California.
Jean Y
JY
Tang
D000368:Aged; D000369:Aged, 80 and over; D000813:Anilides / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D005153:Facial Neoplasms / Q000188:drug therapy* / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D015580:Mohs Surgery; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D011725:Pyridines / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D047368:Tumor Burden
D000813:Anilides; D000970:Antineoplastic Agents; C538724:HhAntag691; D011725:Pyridines